Emmanuel Hanon leads GSK Vaccines Research and Development (R&D) organisation and has end-to-end responsibility for discovery, early and late-stage development, regulatory and medical affairs activities. He is based in Rixensart, Belgium.
Emmanuel is a scientist at heart; he works at creating the right environment for transforming innovative ideas into impactful vaccine technologies that help improve public health around the globe. He is leading scientists across three global R&D centres which are pushing the boundaries of new science and technology in the field of vaccines.
GSK Vaccines R&D organisation manages the complex process of innovation, with more than 110 external scientific collaborations that are vital to innovation. Most of GSK Vaccines have been developed in partnership with leading experts across the globe. GSK has a robust pipeline of 15 innovative candidate vaccines and is also strongly engaged in collaborations to develop adjuvanted COVID-19 vaccines.
Prior to joining GSK, Emmanuel obtained his PhD in 1997 from the University of Liège with research and a thesis on bovine herpesvirus. He then embarked on a post-doctorate in the field of retrovirology at Imperial College London for two years.
Emmanuel joined GSK Vaccines in 2001, taking on the role of increasing responsibility in Immunology and Human Cell mediated immunity before leading the Viral Vaccines programme in R&D. He was appointed Director of the Influenza Franchise in 2006, with primary responsibility for the clinical and commercial development of seasonal and pandemic influenza vaccines. After heading the Elderly vaccines franchise between 2007 and 2009, playing a critical role in the development of GSK’s flu pre-pandemic and pandemic strategy for the elderly, he was appointed Senior Vice President of the GSK Vaccines Research and Development (R&D) organisation, a position he has held since October 2014.